Royal Marsden Nhs Foundation Trust

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study tests whether adding the experimental drug ipatasertib to standard hormone therapy and targeted drugs can help people with a certain type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. It includes 57 participants whose cancer did not re…

This early-stage trial tests the safety of combining the immunotherapy drug pembrolizumab with radiation therapy for people with advanced bladder cancer. About 34 patients with either locally advanced or metastatic disease will receive pembrolizumab before and during radiation, t…

This study tests a surgical technique called tongue base mucosectomy, combined with detailed tissue analysis, to find the original site of head and neck cancers that have spread to lymph nodes but have no known primary source. About 100 patients will undergo this procedure, and r…

This study looks at whether melanoma patients who received immunotherapy might have heart problems years later. Researchers will invite 60 people who finished treatment 2 to 10+ years ago to undergo heart tests. The goal is to see if it's possible to study these long-term side ef…

This observational study follows 170 men with metastatic hormone-sensitive prostate cancer who are taking apalutamide as part of their standard care. Researchers will measure PSA levels and use questionnaires to assess fatigue, thinking skills, and quality of life over two years.…